The ability to develop novel recombinant proteins able to deliver a clostridial or tetanus neurotoxin protease into a cell of choice and thereby inhibit vesicle fusion and secretion from the selected target cell with a prolonged duration of action opens up a wide range of opportunities to develop novel proteins of therapeutic potential for the treatment of a wide variety of chronic diseases.
Syntaxin has already exemplified the technology for inhibition of neurotransmitter release from peripheral pain nerves, developing molecules with analgesic activity in established models of pain and the potential for development as long acting analgesics for the relief of chronic pain. This opportunity has been licensed to Allergan Inc. and has completed Phase I clinical trials in the US.
In addition to its successful progression of the pain opportunity for its technology, Syntaxin is working to advance the utility and application of its expertise and technology to new therapeutic areas and targets. It has already developed proteins able to inhibit secretion in a wide range of different cell types. In particular, Syntaxin has demonstrated the effectiveness of its technology to produce proteins able to block secretion from neuroendocrine and endocrine cells involved in a variety ofendocrine disorders including endocrine tumours.
If you are interested in collaborating with Syntaxin to explore the unique therapeutic benefits of our technology, please contact us.